Dorzagliatin vs Globalagliatin Hydrochloride
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: Glucokinase · full Type 2 Diabetes pipeline
Dorzagliatin · Huatangning
Marketed by Hua Medicine under a licence from Roche
NCT04531631 · Phase 2 · completed
The study used randomized, triple-blind, placebo-controlled crossover treatment, but enrolled only 18 participants and measured a mechanistic insulin-response biomarker rather than a clinical diabetes outcome. Because the registry provides no primary-endpoint results, it is not possible to determine whether the comparison met its prespecified endpoint.
Reported efficacy
first phase insulin response to glucose (10 mins): Acute (first-phase) insulin response to glucose, AIRg, dorzagliatin vs placebo. GCK-MODY group (n=8): 226.1 ± 64.3 vs 179.4 ± 117.7 pmol/L, P = 0.164. Type 2 diabetes group (n=10): -2.3 ± 22.6 vs 31.5 ± 22.1 pmol/L, P = 0.006 (dorzagliatin lower than placebo). (missed)
Result source: NCT04531631
Globalagliatin Hydrochloride
Developed by Eli Lilly and partners
NCT03414892 · Phase 1 · completed
Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Reported efficacy
the mean change in glucose area under curve (AUC) from baseline. (28 days): Phase Ib, 28-day multiple ascending dose study of globalagliatin (glucokinase activator) in 24 Chinese T2DM patients (3:1 randomization, NCT03414892): high-dose globalagliatin significantly reduced FPG by LS mean -4.08 mmol/L (95% CI -5.05 to -3.12, P<0.01) vs placebo, plus significant reductions in 24-h glucose AUC and glycated albumin; mildly elevated incidences of hypoglycemia and hypertriglyceridemia; well tolerated with favorable PK. (met)
Result source: NCT03414892
Results for Type 2 Diabetes
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Dorzagliatin | Globalagliatin Hydrochloride |
|---|---|---|
| HbA1c, change | —Not posted · NCT03173391 | —Not reported |
| Body weight, change (kg) | —Not posted · NCT03173391 | —Not reported |
| HbA1c below 7% | —Not posted · NCT03173391 | —Not reported |
| Fasting plasma glucose, change | —Not posted · NCT03173391 | —Not reported |
| 3-point MACE (% with event) | —Not posted · NCT03173391 | —Not reported |
HbA1c, change
- Dorzagliatin
- —Not posted · NCT03173391
- Globalagliatin Hydrochloride
- —Not reported
Body weight, change (kg)
- Dorzagliatin
- —Not posted · NCT03173391
- Globalagliatin Hydrochloride
- —Not reported
HbA1c below 7%
- Dorzagliatin
- —Not posted · NCT03173391
- Globalagliatin Hydrochloride
- —Not reported
Fasting plasma glucose, change
- Dorzagliatin
- —Not posted · NCT03173391
- Globalagliatin Hydrochloride
- —Not reported
3-point MACE (% with event)
- Dorzagliatin
- —Not posted · NCT03173391
- Globalagliatin Hydrochloride
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Dorzagliatin's landscape · Globalagliatin Hydrochloride's landscape